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ABSTRACT
Antipsychotics (AP) are widely used to treat schizophrenia and other 
psychiatric disorders. However, the association between the AP use and mortality 
risk is controversial. We searched PubMed, EMBASE, MEDLINE, PsycINFO, CINAHL, 
the Cochrane Library and four Chinese databases from inception to June 2016. All 
observational cohort or case–control studies reporting data on mortality outcomes in 
individuals exposed to AP drugs were included. This systematic review included 68 
studies involving 4,812,370 participants. Sixty-seven studies reported confounding 
factors, the most common being age, sex, race, concomitant medications, and 
comorbidities. For all-cause mortality, current users of AP and conventional 
antipsychotics (CAP) had higher mortality risk than did non-AP users [AP users: RR, 
1.50; 95% CI, 1.12 to 1.99; CAP users: RR, 1.53; 95% CI, 1.16 to 2.04]. However, 
the association between the current use of atypical antipsychotics (AAP) and the 
mortality was of borderline significance, and there was no significant difference 
for past users of AP. Mortality was higher in current CAP users than in current AAP 
users. For cardiac death and sudden death, current AP and CAP users also had 
higher mortality risk than non-AP users. A subgroup analysis showed a possible 
increased risk in patients with Parkinson’s, but not in those with dementia, 
Alzheimer’s disease, schizophrenia, delirium or stroke. An increased risk of all-cause 
mortality for patients ≧65 years may also exist. AP exposure is associated with an 
approximately 1.5-fold increased mortality risk. This increased risk may be particularly 
prominent in patients with Parkinson’s and those over 65 years old. Further studies 
are required to evaluate the mortality risk for individual AP drugs and diseases.
INTRODUCTION
Antipsychotics, including conventional antipsychotics 
(CAP) and atypical antipsychotics (AAP), are widely used to 
treat schizophrenia, behavioral and psychological symptoms 
in patients with dementia, and other psychotic disorders 
[1–3]. Up to 46% of elderly patients in nursing homes are 
treated with AP [4–7] and 90% of nursing home residents 
with dementia have at least one behavioral or psychological 
symptom, meaning patients are prescribed AP [8].
                                                       Meta-Analysis
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However, concerns about the safety of AP 
has always been a controversial topic. In 2005, 
Schneider et al. [9] reported AAP use was associated 
with a 1.5-fold increased risk of death compared with 
placebo in elderly people with dementia based on data 
from 15 randomized controlled trials (RCTs). However, 
Hulshof et al. [10] reported that CAP did not increase 
the risk of mortality in elderly patients. As these 
systematic reviews only included RCTs, they reflect the 
risk of mortality across the short term. Some systematic 
reviews have explored the association between AP use 
and risk of mortality by including up-to-date evidence 
from observational studies. Trifiro et al. [11] provided 
mixed results on the safety of AP to treat psychological 
symptoms of dementia. Zhai et al. [12] reported that 
AP did not increase the risk of death in patients with 
Alzheimer’s disease. However, the former systematic 
reviews [11] only described the results of included studies 
and lacked a quantitative analysis. 
Current systematic reviews only focused on 
the mortality for the specific disease and the results 
were controversial, so if our study includes all types 
of research without limiting the type of disease, it will 
provide more information about the overall risk of death 
and some important outcomes. Moreover, one systematic 
review [12] already reported a lot of heterogeneity in 
study results, but it did not well explain the source of 
heterogeneity, we will use the method of meta regression 
to study potential explanations more explicitly and 
more extensively than they did in the current analysis. 
In addition, several observational studies have been 
recently published that investigate the risk of mortality 
associated with AP use. Therefore, we conducted an 
updated systematic review of observational studies by 
combining all available data to derive an estimation of 
the association between AP use and long term risk of 
mortality in real world clinical practice.
RESULTS
Results of the literature search
Initially, we identified 4498 articles. After removing 
duplicates, screening titles and abstracts, and reading 
full texts, 68 observational studies (n = 4,812,370) met 
the inclusion criteria, including 51 cohort studies (n = 
2,033,567) and 17 case-control studies (n = 2,778,803) 
(Figure 1).
Study characteristics 
Supplementary Table 1 presents the characteristics 
of included studies. We included 68 studies involving 
4,812,370 participants, with sample sizes varying from 
153 to 1,716,552 (median 5,949). The residence of the first 
author varied as follows: Europe (35/68, 51.5%), North 
America (25/68, 36.8%), Oceania (4/68, 5.9%), and Asia 
(4/68, 5.9%).
The age of participants ranged from 10 to 100 years. 
Forty-nine studies reported a follow up period ranging 
from 30 days to 16 years, with the following distribution: 
3 months or less (7/49, 14.3%), 6 months (15/49, 30.6%), 
1 year (4/49, 8.2%), 1–5 years (17/49, 34.7%), and 
>5 years (6/49, 12.2%). Sixty-seven studies reported 
confounding factors, the most common being age, sex, 
race, concomitant medications, and comorbidities.
Quality assessment (Supplementary Table 2)
Of the 68 studies, 66 (97.1%) were rated as high 
quality (scoring 8.04 ± 0.69), 2 (2.9%) were of medium 
quality (scoring 6), and there were no low quality studies. 
A maximum score for the Newcastle-Ottawa Scale was 
achieved by 17 studies (25%). All studies gained the 
maximum score in the selection outcome, 37 studies had 
the maximum score in the comparability outcome, and 33 
studies had the maximum score in the exposure outcome.
Antipsychotic drugs and mortality risk
AP users vs. AP non-users
All-cause mortality risk was reported by 34 studies 
(n = 2,500,546), including 21 cohort studies (n = 679,683) 
and 13 case-control studies (n = 1,820,863). The pooled 
RR for 34 observational studies was 1.50 [95% CI, 1.12 to 
1.99; I2, 99.3%] for current AP users compared with those 
not exposed to AP (Figure 2).
Seven studies (n = 409,294), including two cohort 
studies (n = 384,299) and five case-control studies (n = 
24,995) reported cardiac death risks for patients prescribed 
AP, and the risk for current AP use was higher than that for 
AP non-users [RR, 2.10; 95% CI, 1.29 to 3.42; I2, 76.7%].
Only three case-control studies (n = 11,789) reported 
the outcome of sudden death. Our meta-analysis showed 
that the risk of sudden death for current AP use was higher 
than that for AP non-users [RR, 3.70; 95% CI, 2.68 to 
5.12; I2, 0%] (Figure not shown).
Current CAP users vs. AP non-users
All-cause mortality risk for CAP users was reported 
in 20 studies (n = 856,461), including 14 cohort studies (n 
= 788,566) and 6 case-control studies (n = 67,895). The 
risk for current CAP users was higher than that for AP 
non-users [RR, 1.53; 95% CI, 1.16 to 2.04, I2, 96.6%].
Cardiac death was reported in two studies (n = 
384,299) and sudden death was also reported in two studies 
(n = 184,046). Current CAP users had higher rates of cardiac 
death and sudden death compared with AP non-users [RR, 
1.90; 95% CI, 1.52 to 2.30; I2, 0%; RR, 2.60; 95% CI, 1.01 
to 6.74; I2, 65.6%, respectively] (Figure not shown).
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Current AAP users vs. AP non-users
All-cause mortality risk for current AAP users 
was reported in 26 studies (n = 1,080,378), including 19 
cohort studies (n = 978,576) and 7 case-control studies (n 
= 101,802). The results showed the risk for current AAP 
users did not differ significantly from that for AP non-
users [RR, 1.31; 95% CI, 1.00 to 1.72; I2, 98%].
In studies of AAP use, two studies (n = 384,299) 
reported the outcome of cardiac death and two studies (n 
= 186,625) reported the outcome of sudden death. The 
results revealed that, compared with AP non-users, current 
AAP users did not have higher rates of cardiac death [RR, 
1.23; 95% CI, 0.57 to 2.65; I2, 84.8%], but did have higher 
rates of sudden death [RR, 1.94; 95% CI, 1.58 to 2.39; I2, 
0%] (Figure not shown).
Current CAP users vs. AAP users
All-cause mortality in CAP and AAP users was 
reported in 19 studies (n = 1,381,688), including 16 cohort 
studies (n = 423,901) and three case control studies (n = 
957,787). The results suggested that there was a higher risk 
all-cause mortality in current CAP users than in current AAP 
users [RR, 1.43; 95% CI, 1.25 to 1.64; I2, 97.9%] (Figure 3).
Cardiac death in CAP and AAP users was reported 
by two studies (n = 959,279) and sudden death in CAP 
and AAP users was reported by one study (n = 1,624). The 
results showed that the risk of both for current CAP users 
was higher than that for AAP users [RR, 1.17; 95% CI, 
1.07 to 1.28; I2, 45.4%; RR, 1.72; 95% CI, 1.02 to 2.89; 
respectively] (Figure not shown).
Past AP users vs. AP non- users
All-cause mortality risk for past AP use was 
reported in seven studies (n = 765,520), including six 
cohort studies (n = 760,503) and one case-control study 
(n = 5,017). The results showed the risk for past AP use 
did not differ significantly from that for AP non-use 
[RR, 1.01; 95% CI, 0.91 to 1.11; I2, 0%] (Supplementary 
Figure 1).
Cardiac death in past AP use was reported in three 
studies (n = 670,654). The results showed that the risk 
for past AP use did not differ significantly from that of 
AP non-use [RR, 1.02; 95% CI, 0.85 to 1.21; I2, 24.6%] 
(Figure not shown).
Subgroup analyses 
Mortality among different diagnoses
In the subgroup analyses for mortality in patients 
with different diseases (Figure 4), our meta-analysis 
showed that, compared with AP non-users, only patients 
with Parkinson’s (three studies, n = 16,407) have higher 
all-cause mortality associated with AP use [RR, 2.10; 
95% CI, 1.12 to 3.95; I2, 88.5%]. Although current AP 
users with dementia (seven studies, n = 12,655), AD 
(five studies, n = 11,781), schizophrenia (seven studies, 
n = 191,557), and delirium (two studies, n = 3,360) had 
an increased mortality risk, but the differences were not 
significant.
Mortality according to age
In the subgroup analyses for mortality in patients 
of different ages (Supplementary Figure 2), compared 
with AP non-users, AP use increased the risk of all-cause 
mortality in patients over 65 years old (21 studies, n = 
1,909,183), but not in patients under 65 years old (seven 
studies, n = 403,725) [RR, 1.59; 95% CI, 1.13 to 2.23; 
I2, 98.7%; RR, 1.09; 95% CI, 0.67 to 1.78; I2, 94.6%, 
respectively].
Meta-regression 
While conducting our meta-analysis of the risk of 
all-cause mortality in AP users compared with AP non-
users, we observed high heterogeneity among the studies 
(I2, 99.3%). Therefore, we conducted a meta-regression 
using the covariates of study design, age, disease, and 
comorbidities. The results showed that none of these 
variables had a significant impact on between-study 
heterogeneity (P values, 0.889; 0.295; 0.173; and 0.140, 
95% CI, -0.67-0.58, -0.22-0.70, -0.05-0.27,-0.06-0.44, 
respectively).
Sensitivity analyses
In a sensitivity analysis that excluded one study at 
a time, the pooled RR for all-cause mortality in patients 
ranged from 1.45 (95% CI, 1.08 to 1.94) to 1.62 (95% CI, 
1.23 to 2.14) (Supplementary Figure 3). All point estimates 
lay within the 95% CI of the combined analysis, indicating 
that no individual study had excessive influence on the 
pooled effect between AP use and all-cause mortality risk.
Publication bias 
Supplementary Figure 4 shows the results of our 
analysis of publication bias. Visual inspection of the 
funnel plot showed it to be asymmetrical. Egger’s test 
also showed no evidence of publication bias for all-cause 
mortality (P = 0.095).
DISCUSSION 
Statement of main findings
In our study, the existing evidence indicated that 
current AP users have an approximately 1.5-fold increased 
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risk of mortality than AP non-users. There were no 
significant differences in mortality risk for current AAP 
users and past AP users compared with AP non-users. 
However, the mortality risk of current CAP users was 
higher than that for current AAP users. Moreover, current 
CAP users also had higher rates of cardiac death and 
sudden death than AP non-users. We also found that an 
increased mortality risk may exist in AP users diagnosed 
with Parkinson’s but not in those with dementia, AD, 
schizophrenia, delirium, or stroke. There may also be an 
increased risk of all-cause mortality in patients over 65 
years old. Although we have try to included all kinds of 
studies, the asymmetrical funnel plot indicated publication 
bias, the reason may be that some conference papers and 
papers published in other languages could not be included 
through our search.
Quality of the evidence
In general, the studies included in this systematic 
review were of good quality. However, some problems 
did exist. First, in the exposure outcome, some studies did 
not control for important confounding factors (i.e., age, 
comorbidities, or concomitant medications). Second, the 
follow-up period in some cohort studies was short, so 
the outcome of interest might not have occurred during 
the period of observation. Third, although loss to follow 
up is common in cohort studies, few studies tested the 
Figure 1: Flowchart of the search strategy.
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comparability for the reason and proportion of loss of 
follow up between the exposure group and control group. 
Comparison with other studies
Several systematic reviews have investigated 
the association between AP use and risk of mortality. 
However, all previous systematic reviews have only 
focused on specific diseases. Schneider’s study [9] 
reported that CAP use carries a 1.5 times higher incidence 
of mortality in elderly people with dementia for relatively 
brief periods of less than 8 to 12 weeks, because it 
included six published trials and nine unpublished 
trial and all but one of the trials were sponsored and 
conducted by drug manufacturers. The likely reasons 
for the delays in publication were that most did not 
show statistically significant results on their primary 
efficacy outcomes, perhaps lessening the enthusiasm 
of the sponsors to submit the manuscripts. Moreover, 
death did not differ between the 6 published trials (OR, 
1.42; 95% CI, 0.80-2.51) and the 9 unpublished trials 
(OR, 1.63; 95% CI, 1.00-2.65). Therefore the funnel 
plot of the log Ors against sample size was symmetrical 
around the mean overall effect, thus not providing 
evidence for selection bias in schneider’s study, but in 
our study, visual inspection of the funnel plot showed 
it to be asymmetrical and publication bias may exist. 
These were the most important reasons for the difference 
between the results of this study and our findings. Trifiro 
et al. [11] conducted an updated review of observational 
studies to examine the existing literature on the safety of 
antipsychotic drug use in dementia patients and found 
there is indeed a difference between the risks associated 
with individual antipsychotic drugs in psychological 
symptoms of dementia. In our review, we also found a 
similar increased risk among AP use over the long term. 
Another systematic review [12] focused on the mortality 
risk of patients with Alzheimer’s disease prescribed AP, 
reporting that AP use may not increase the death risk 
for these patients. This is consistent with our findings, 
as we also did not find an increased mortality risk for 
patients with Alzheimer’s disease. However, we found an 
increased risk of mortality in patients with Parkinson’s 
and those aged over 65 years old. In addition, we found 
that past AP use did not have an increased risk of 
mortality.
Limitations 
There are some limitations to our study. (1) 
Only studies published in English were included, and 
thus some non-English studies may have been missed. 
However, most high quality research is generally 
published in English journals. (2) Although statistical 
analyses were adjusted for several confounding 
factors, other potential confounding factors (i.e., 
genetic factors, race, comorbidity, follow-up duration) 
could not be entirely ruled out. (3) There was limited 
information about the dosages of AP exposure, so we 
could not conduct a dose-response analysis to assess 
the influence of different doses on mortality. Therefore, 
further studies should be conducted to overcome these 
shortcomings.
Implications for future study
First, there was large heterogeneity when pooling 
the data from included studies. Even if most included 
studies had adjusted for potential confounding factors, 
some clinical differences in patients (i.e., age, disease, the 
setting of participants, comorbidities) could lead to clinical 
heterogeneity. Therefore, future research should focus on 
patients with specific diseases and ages to reduce clinical 
heterogeneity. Second, other potential confounding 
factors should be investigated. Third, we found about 
half of all studies had a follow up within one year, and 
only 12% studies had a follow up period of more than five 
years. Therefore, suitable follow up durations should be 
determined to demonstrate the risk of mortality in AP use. 
Lastly, it is necessary to establish a global multi-center 
registration platform to observe the risk of death over the 
long term.
MATERIALS AND METHODS
Inclusion and exclusion criteria
Types of studies
We included observational cohort and case–control 
studies published in English that reported data on mortality 
outcomes. Studies were excluded if (1) the outcomes of 
interest were not reported; (2) the effect size (i.e., odds 
ratio (OR), relative risk (RR) or hazard risk (HR) with 
95% confidence intervals (CI) was not provided, or if these 
values could not be calculated from the data provided.
Types of participants
Patients exposed to AP were included. There was 
no restriction with respect to indications for AP use (i.e., 
schizophrenia, behavioral and psychotic disturbances in 
dementia, delirium, stroke and Parkinson’s).
Types of exposure and comparisons
The exposure of interest was AP use, including both 
CAP and AAP. The comparisons were as follows: (1) AP 
use vs. AP non-use; (2) CAP use vs. AP non-use; (3) AAP 
use vs. AP non-use; (4) AAP use vs. CAP use; (5) past AP 
use vs. AP non-use. 
Oncotarget15106www.oncotarget.com
Types of outcome measurements
The outcomes of interest were all-cause mortality, 
cardiac death, and sudden death. If there were different 
periods of follow up, we used the data from the last follow 
up.
Search strategy
Two reviewers independently identified studies 
through searches of PubMed, EMBASE, MEDLINE, 
PsycINFO, CINAHL, the Cochrane Library and the 
Chinese Biomedical Literature Database, the China 
Knowledge Resource Integrated Database, the VIP 
Database, and the Wanfang Database from inception 
to June 2016, with no limits on date/time, language, 
document type, or publication status. We also searched 
for additional studies in the reference lists of all identified 
publications, including relevant meta-analyses and 
systematic reviews. Keywords were identified using 
experts’ opinion, literature review, controlled vocabulary 
(Medical Subject Headings = MeSH, Excerpta Medica 
Figure 2: All-cause mortality of current AP user vs AP non-users.
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Tree = EMTREE, APA Thesaurus, and CINHAL 
Headings), and reviewing the primary search results. 
Search strategies are reported in the Supplement.
Selection of studies and data extraction
Two reviewers independently screened the 
titles and abstracts of every record. Full articles were 
obtained when either information provided in the title 
or the abstract conformed to the selection criteria 
outlined above, or when inclusion eligibility could 
not be ascertained because of limited information. For 
included studies, data were independently extracted by 
each reviewer and entered into a standardized form. The 
data extraction form included the following: (1) general 
study characteristics; (2) general patient characteristics; 
(3) study design; (4) sample size; (5) exposures and 
comparisons; and (6) outcomes of interest with effect 
size and 95% CI. Discrepancies were resolved by 
consensus.
Quality assessment
Two reviewers independently evaluated the 
methodological quality of identified studies. The 
quality of observational studies was assessed using the 
Newcastle–Ottawa quality assessment scale (http://www.
ohri.ca/programs/clinical_epidemiology/oxford.asp) 
as recommended by the Cochrane Collaboration [13]. 
The maximum score on the Newcastle–Ottawa quality 
assessment scale is 9. In our review, a score of 7–9 was 
considered as high quality, 4–6 as moderate quality, and 
Figure 3: All cause mortality of current CAP users vs. AAP users.
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0–3 as low quality. Disagreements were discussed and 
agreed upon through consensus [14].
Statistical methods
The outcome of interest was the effect of AP on the 
incidence of all-cause death, expressed as an OR, RR, or 
HR with 95% CIs. RRs were used as the common measure 
of association across studies. To do this, the HR was 
directly considered as an RR [15–17]. Death is a rare event, 
so the OR is approximately equal to RR. Therefore, an 
overall estimate was obtained from a random-effects model. 
Subgroup analysis was performed according 
to the type of study (i.e., cohort study, case-control 
study), patient population (i.e., dementia, schizophrenia, 
Parkinson’s), and age (age ≥65 years vs. age <65 years). 
Meta-regression analyses were used to investigate 
whether potential heterogeneity could be explained. We 
will conduct a meta-regression using the covariates of 
study design, age, disease, and comorbidities.  Sensitivity 
analyses were conducted to evaluate the stability of 
results by excluding one study at a time. Publication bias 
was assessed using visual inspection of funnel plots and 
Egger’s test.
Meta analyses were performed and presented using 
Stata 12.0 (Stata Corporation, College Station, Texas, 
USA).
Figure 4: All cause mortality of current AP user vs AP non-users for different disease.
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CONCLUSIONS
AP exposure is associated with an approximately 1.5-
fold increased risk of mortality. This increased risk may be 
seen particularly in patients with Parkinson’s and those over 
65 years old. Because of large heterogeneity in available 
studies, further research investigated on the risk of mortality 
for individual AP and different diseases is a priority.
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